Retatrutide 30 mg + Tirzepatide 30 mg
RET60
Lyophilized peptide for use under a licensed healthcare provider. Choose single ampule/vial or box of 10. Sourced via Ares Technology Limited (Hong Kong) / Healthtide Biotech manufacturing list dated 7 October 2026. Specification: 60 mg × 10 vials.
- • Prescription / clinician-supervised pathway
- • Same LIRAVEXIN cart and checkout as pen packages
- • Not medical advice — individual suitability is determined by your clinician
Clinical reference (clinician-supervised)
Clinic convenience combination reflecting the named components. See individual monographs for each ingredient’s evidence and investigational status. Combination use requires a single supervising clinician plan—never stack duplicate incretins casually.
No unique FDA label for the blend. Dose each active as the clinician would for components (or a written combination protocol). Vial total mg is the sum of labeled actives—not a single ‘peptide dose.’
Per clinician protocol (often aligned to the most restrictive component schedule).
Typically subcutaneous after pharmacy preparation under licensed pathway.
Typical clinical / literature ranges under clinician supervision — not a prescription and not a DIY dosing guide. Individual dosing is determined solely by the treating clinician.
Liravexin USD for this pack (wholesale comparison · source × 3). Item is added to your shared cart for checkout coordination with your clinician pathway.
Or continue to checkout →